InvestorsHub Logo

seve333

05/10/23 11:29 AM

#408575 RE: mrmainstreet #408573

Most everyone says Denner had a plan in place before the proxy and knows exactly what he is doing. So it cannot be both he either had a plan or he did not. It seems very hard to believe he came into this blind and is now going to have to spend five years trying to dig the company out of the mess is was in just to maybe get 10 a share.

JRoon71

05/10/23 11:42 AM

#408578 RE: mrmainstreet #408573

MMS, I 100% agree that PWO had to go. I firmly believe, after everything that came out during the proxy battle, that he was the biggest problem.

And I honestly think that maybe Denner was OK with most of the board (and KM), based on the comment about the board and KM resigning unexpectedly.

And I also agree (hope) that they are "under promising and over delivering". But the total silence has been deafening. Even the message he sent out yesterday was really just a "don't worry we are working on it" message, with nothing concrete at all. That's my biggest concern. It is NOT instilling any faith that they have a plan in place. But I REALLLLLY hope that they are just quietly going about their work, and one day we will wake up to some fantastic news.

ziploc_1

05/10/23 11:44 AM

#408580 RE: mrmainstreet #408573

PWO has never explained why he didn't support Marjac and EPADI in their appeal case base on the fraud that Hikma had used to win their decision at the ninth circuit.

Supporting that case would have been at little or no cost to Amarin ...PWO placed his desire to avoid embarrassing Kennedy and Covington ahead of the interests of Amarin's shareholders...after these attorneys exhibited legal malpractice in not detecting the fraud and calling the court's attention to the fraud.

Judge Du, who was uniformed of the fraud during the case, cited the fraudulently cropped document from the Mori study in her decision to invalidate Amarin's high trig patent for Vascepa...thus opening the way for generics to continuously infringe on Amarin's patent for patent to treat CVDs...as they do to this day.